PT3464309T - Derivados de nucleósidos de fosforamidato como agentes anticancerígenos - Google Patents

Derivados de nucleósidos de fosforamidato como agentes anticancerígenos

Info

Publication number
PT3464309T
PT3464309T PT177285962T PT17728596T PT3464309T PT 3464309 T PT3464309 T PT 3464309T PT 177285962 T PT177285962 T PT 177285962T PT 17728596 T PT17728596 T PT 17728596T PT 3464309 T PT3464309 T PT 3464309T
Authority
PT
Portugal
Prior art keywords
anticancer agents
nucleoside derivatives
phosphoramidate nucleoside
phosphoramidate
derivatives
Prior art date
Application number
PT177285962T
Other languages
English (en)
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of PT3464309T publication Critical patent/PT3464309T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PT177285962T 2016-06-01 2017-05-31 Derivados de nucleósidos de fosforamidato como agentes anticancerígenos PT3464309T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1609601.8A GB201609601D0 (en) 2016-06-01 2016-06-01 Phosphoramidate compounds

Publications (1)

Publication Number Publication Date
PT3464309T true PT3464309T (pt) 2020-06-23

Family

ID=56410850

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177285962T PT3464309T (pt) 2016-06-01 2017-05-31 Derivados de nucleósidos de fosforamidato como agentes anticancerígenos

Country Status (26)

Country Link
US (2) US10906929B2 (pt)
EP (1) EP3464309B1 (pt)
JP (2) JP7025351B2 (pt)
KR (1) KR20190015353A (pt)
CN (1) CN109195981A (pt)
AU (1) AU2017273117B2 (pt)
BR (1) BR112018074961A2 (pt)
CA (1) CA3025440A1 (pt)
CL (1) CL2018003404A1 (pt)
DK (1) DK3464309T3 (pt)
EA (1) EA036409B1 (pt)
ES (1) ES2801448T3 (pt)
GB (1) GB201609601D0 (pt)
HR (1) HRP20200983T1 (pt)
HU (1) HUE051335T2 (pt)
IL (1) IL263121B (pt)
MX (1) MX2018014859A (pt)
MY (1) MY198880A (pt)
PH (1) PH12018502606A1 (pt)
PL (1) PL3464309T3 (pt)
PT (1) PT3464309T (pt)
SA (1) SA518400552B1 (pt)
SG (1) SG11201810018TA (pt)
SI (1) SI3464309T1 (pt)
WO (1) WO2017207986A1 (pt)
ZA (1) ZA201807652B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
JP6646668B2 (ja) 2014-11-28 2020-02-14 ヌカナ ピーエルシー 抗がん性化合物としての新規な2’および/または5’アミノ酸エステルホスホロアミダート3’−デオキシアデノシン誘導体
EP3464271B1 (en) 2016-05-31 2020-05-13 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
HRP20220367T1 (hr) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
WO2019172835A1 (en) * 2018-03-09 2019-09-12 Medivir Aktiebolag Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN110845560B (zh) * 2019-11-21 2021-08-24 广东中科药物研究有限公司 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309525A2 (en) * 2000-07-13 2003-05-14 Micrologix Biotech, Inc. Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
BRPI1004575A2 (pt) 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
US8933053B2 (en) * 2011-03-01 2015-01-13 Nucana Biomed Limited Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
RU2016125213A (ru) 2013-11-27 2017-12-29 АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Нуклеотиды для лечения рака печени
WO2015181624A2 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
PL3119794T3 (pl) 2014-06-25 2018-04-30 NuCana plc Preparat zawierający prolek gemcytabiny
JP6646668B2 (ja) * 2014-11-28 2020-02-14 ヌカナ ピーエルシー 抗がん性化合物としての新規な2’および/または5’アミノ酸エステルホスホロアミダート3’−デオキシアデノシン誘導体
PT3307734T (pt) 2015-06-09 2020-02-25 Abbvie Inc Moduladores de recetores nucleares (ror) para o tratamento de doenças inflamatórias e autoimunes
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments

Also Published As

Publication number Publication date
ZA201807652B (en) 2021-05-26
US10906929B2 (en) 2021-02-02
DK3464309T3 (da) 2020-06-29
JP7025351B2 (ja) 2022-02-24
JP2022051936A (ja) 2022-04-01
ES2801448T3 (es) 2021-01-11
MY198880A (en) 2023-10-02
PH12018502606A1 (en) 2019-10-21
HUE051335T2 (hu) 2021-03-01
IL263121A (en) 2018-12-31
US20210130387A1 (en) 2021-05-06
PL3464309T3 (pl) 2020-10-19
SA518400552B1 (ar) 2021-12-08
GB201609601D0 (en) 2016-07-13
HRP20200983T1 (hr) 2020-12-11
EA201892745A1 (ru) 2019-05-31
AU2017273117B2 (en) 2021-02-04
CA3025440A1 (en) 2017-12-07
WO2017207986A1 (en) 2017-12-07
BR112018074961A2 (pt) 2019-03-12
CL2018003404A1 (es) 2019-04-05
EP3464309B1 (en) 2020-06-10
AU2017273117A1 (en) 2018-12-06
EA036409B1 (ru) 2020-11-06
MX2018014859A (es) 2019-03-07
EP3464309A1 (en) 2019-04-10
CN109195981A (zh) 2019-01-11
SG11201810018TA (en) 2018-12-28
KR20190015353A (ko) 2019-02-13
IL263121B (en) 2021-10-31
US20190375779A1 (en) 2019-12-12
SI3464309T1 (sl) 2020-10-30
JP2019517510A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
ZA201705092B (en) Substituted nucleoside derivatives useful as anticancer agents
IL263121B (en) History of nucleoside phosphoramidate as anticancer agents
IL282167A (en) Metabolized carbonucleosides and their use for cancer treatment
ZA201606530B (en) 3-phenyl-benzofuran-2-one derivatives containing phosphorus as stabilizers
IL253381A0 (en) History of h9-pyrrolo-dipyridine
ZA201801465B (en) 3-phenyl-benzofuran-2-one derivatives containing phosphorus as stabilizers
SG11201710198YA (en) Anticancer agent
HK1255108A1 (zh) 核苷類藥物的氨基磷酸酯衍生物的製劑
IL249581A0 (en) History of isoindolinones used as antiviral agents
ZA202002898B (en) Anticancer agents
IL263157A (en) Anticancer compositions
EP3257515A4 (en) Antitumor agent
EP3515904C0 (en) BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS
IL251005B (en) Pyrido-oxazinone derivatives
EP3287143A4 (en) Ckap4-molecular-targeted antitumor agent
HK1253336A1 (zh) 吲哚並吡咯啉抗腫瘤藥物
GB2578973B (en) Pyrrolopyrimidines as antitumor agents
PL3280261T3 (pl) Przeciwnowotworowe środki terapeutyczne
IL274808A (en) Phosphoramidate diphosphate salts of nucleosides as anticancer compounds
GB201505028D0 (en) Planetary steering differential